+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antivenoms - Global Strategic Business Report

  • PDF Icon

    Report

  • 196 Pages
  • October 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309401
The global market for Antivenoms was estimated at US$1.4 Billion in 2023 and is projected to reach US$2.3 Billion by 2030, growing at a CAGR of 7.3% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Antivenoms are specialized biological products that play a critical role in treating envenomations caused by bites or stings from venomous animals, including snakes, spiders, and scorpions. These life-saving treatments work by neutralizing the toxins present in the venom, which, if left untreated, can cause severe illness or even death. The process of creating antivenoms involves injecting a small, non-lethal dose of venom into an animal, typically a horse or sheep, which then produces antibodies against the venom. These antibodies are collected, purified, and used to create the antivenom. Despite the importance of these products, their production is complex and requires specialized facilities, which limits their availability, especially in regions where venomous bites are common. The science behind antivenoms is intricate, as different venoms require specific antibodies, making the production of a universal antivenom virtually impossible. This complexity underscores the essential nature of continued research and development in this field to ensure that effective treatments are available for all types of envenomations.

Why Is Accessibility to Antivenoms Still a Global Challenge?

Accessibility to antivenoms remains a significant global health challenge, particularly in developing countries where venomous bites and stings are more common. Many regions that are most in need of antivenoms suffer from inadequate healthcare infrastructure, leading to delays in treatment that can be fatal. The cost of antivenoms is another barrier, as the expensive production process translates into high prices that are often unaffordable for those in low-income areas. Furthermore, the lack of investment in this area has led to a scarcity of antivenom supplies, with many pharmaceutical companies discontinuing production due to low profit margins. This scarcity is exacerbated by the fact that antivenoms have a limited shelf life, which complicates distribution and storage in remote areas. Additionally, the diversity of venoms and the specificity required in antivenom production mean that not all regions have access to the necessary types of antivenom. These challenges highlight the urgent need for global collaboration to improve access to these essential medicines, ensuring that people in all regions can receive timely and effective treatment.

Can Innovation Overcome the Current Limitations in Antivenom Development?

Recent years have seen promising advancements in antivenom research and development, driven by a growing recognition of the need for more effective and widely available treatments. Innovations in biotechnology are paving the way for new methods of antivenom production that could address some of the existing challenges. For instance, the use of recombinant DNA technology allows for the creation of monoclonal antibodies that can target specific venom components more precisely, potentially leading to more effective antivenoms with fewer side effects. Additionally, advances in synthetic biology are enabling the development of synthetic antivenoms that do not rely on animal sources, which could reduce costs and improve accessibility. Research into the molecular structure of venom has also opened up possibilities for creating broader-spectrum antivenoms that can neutralize a wider range of venoms. Despite these advancements, significant hurdles remain, particularly in ensuring that these new technologies can be scaled up for widespread use in low-resource settings. The ongoing challenge is to translate these scientific breakthroughs into practical solutions that can be implemented globally.

What Is Driving the Growth of the Antivenom Market?

The growth in the antivenom market is driven by several factors, reflecting both advancements in technology and shifts in global healthcare priorities. One of the primary drivers is the increasing incidence of snakebites and other venomous encounters, particularly in rural areas of Asia, Africa, and Latin America. This has heightened the demand for effective antivenoms, prompting investment in research and development. Additionally, technological advancements, such as the development of monoclonal antibodies and synthetic antivenoms, are expanding the scope of available treatments, making it possible to produce antivenoms that are more effective and easier to distribute. Consumer behavior is also shifting, with a growing awareness of the importance of timely treatment for venomous bites leading to increased demand for these products. Moreover, governmental and non-governmental organizations are placing greater emphasis on addressing neglected tropical diseases, including venomous bites, which is driving funding and support for antivenom production and distribution. Finally, the trend towards personalized medicine is influencing the market, as there is a growing demand for antivenoms that can be tailored to specific types of envenomations, further stimulating market growth.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Snakes Species segment, which is expected to reach US$2.0 Billion by 2030 with a CAGR of a 7.4%. The Scorpions Species segment is also set to grow at 6.9% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $361.0 Million in 2023, and China, forecasted to grow at an impressive 10.8% CAGR to reach $545.0 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Antivenoms Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Antivenoms Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Antivenoms Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Boehringer Ingelheim International GmbH, BTG PLC, CSL Ltd., and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 46 Featured):

  • Boehringer Ingelheim International GmbH
  • BTG PLC
  • CSL Ltd.
  • Merck & Co., Inc.
  • MicroPharm Ltd.
  • Pfizer, Inc.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Antivenoms - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Growing Incidence of Snakebites and Venomous Encounters Spurs Demand for Antivenoms
  • Innovations in Monoclonal Antibody Technology Propels Growth in Antivenom Market
  • Synthetic Antivenoms Expand Addressable Market Opportunity by Reducing Dependence on Animal Sources
  • Advancements in Biotechnology Strengthen Business Case for New Antivenom Developments
  • Increasing Focus on Neglected Tropical Diseases Accelerates Demand for Effective Antivenoms
  • Rising Awareness Among Rural Populations Generates Demand for Accessible Antivenom Treatments
  • Improved Distribution Networks in Remote Areas Throws the Spotlight on Market Expansion Potential
  • Personalized Medicine Trends Propel Growth in Tailored Antivenom Solutions
  • Shelf-Life Limitations of Antivenoms Generate Opportunities for Innovation in Storage Solutions
  • Emergence of Broad-Spectrum Antivenoms Impacts Market Growth Potential
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Antivenoms Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Antivenoms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Antivenoms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Antivenoms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Snakes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Snakes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Snakes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Scorpions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Scorpions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Scorpions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Spiders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Spiders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Spiders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Species by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Polyvalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Polyvalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Polyvalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Monovalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Monovalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Monovalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Anti-Venom Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Anti-Venom Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other Anti-Venom Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
JAPAN
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
CHINA
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: China 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
EUROPE
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Antivenoms by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Antivenoms by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Antivenoms by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
FRANCE
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: France 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
GERMANY
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
SPAIN
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 86: Spain Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Spain Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Spain 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
RUSSIA
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 92: Russia Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Russia Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Russia 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
REST OF EUROPE
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Rest of Europe Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Rest of Europe 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Antivenoms by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Antivenoms by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Antivenoms by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2014, 2024 & 2030
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2014, 2024 & 2030
AUSTRALIA
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Boehringer Ingelheim International GmbH
  • BTG PLC
  • CSL Ltd.
  • Merck & Co., Inc.
  • MicroPharm Ltd.
  • Pfizer, Inc.

Table Information